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Abstract 
Background: Tropomyosin-related kinase A (TRKA) is a nerve growth factor (NGF) receptor that belongs to the tyros-
ine kinase receptor family. It is critical for the correct development of many types of neurons including pain-mediat-
ing sensory neurons and also controls proliferation, differentiation and survival of many neuronal and non-neuronal 
cells. TRKA (also known as NTRK1) gene is a target of alternative splicing which can result in several different protein 
isoforms. Presently, three human isoforms (TRKAI, TRKAII and TRKAIII) and two rat isoforms (TRKA L0 and TRKA L1) have 
been described.
Results: We show here that human TRKA gene is overlapped by two genes and spans 67 kb—almost three times 
the size that has been previously described. Numerous transcription initiation sites from eight different 5′ exons 
and a sophisticated splicing pattern among exons encoding the extracellular part of TRKA receptor indicate that 
there might be a large variety of alternative protein isoforms. TrkA genes in rat and mouse appear to be consider-
ably shorter, are not overlapped by other genes and display more straightforward splicing patterns. We describe 
the expression profile of alternatively spliced TRKA transcripts in different tissues of human, rat and mouse, as well 
as analyze putative endogenous TRKA protein isoforms in human SH-SY5Y and rat PC12 cells. We also characterize a 
selection of novel putative protein isoforms by portraying their phosphorylation, glycosylation and intracellular locali-
zation patterns. Our findings show that an isoform comprising mainly of TRKA kinase domain is capable of entering 
the nucleus.
Conclusions: Results obtained in this study refer to the existence of a multitude of TRKA mRNA and protein isoforms, 
with some putative proteins possessing very distinct properties.
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Background
Tropomyosin-related kinase A (TRKA, official name neu-
rotrophic tyrosine kinase, receptor, type 1, or NTRK1) gene 
encodes the high affinity receptor for a neurotrophin nerve 
growth factor (NGF). TRKA with the highly similar recep-
tors TRKB and TRKC belongs to the group of tyrosine 
kinase receptors. TRKB binds neurotrophins brain-derived 
neurotrophic factor (BDNF) and neurotrophin-4 (NT-4) 
while TRKC is the predominant receptor for neurotrophin 
NT-3, although TRKA and TRKB can also be activated by 
NT-3 [1]. Signaling initiated by the NGF-TRKA complex is 
crucial for the development of pain-mediating sensory neu-
rons [2], postganglionic sympathetic neurons [3] and basal 
forebrain cholinergic neurons [4]. NGF also affects cells of 
non-neuronal tissues, such as epithelial and smooth muscle 
cells, and is very important in thymic tissues [5].
Neurotrophin binding to the TRK extracellular domain 
leads to receptor’s dimerization, activation of its intrinsic 
kinase activity and autophosphorylation. Subsequently, 
the signaling pathways similar for all the TRK receptors 
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are activated. These include the rat sarcoma/mitogen-
activated protein kinase (Ras-MAPK), phosphatidyl-ino-
sitol 3 kinase (PI3K) and phospholipase C-γ1 (PLC-γ1) 
pathways to promote survival and differentiation, and 
adjust synaptic plasticity [6–8].
In addition, several neurotrophin independent signal-
ing events have been described, including transactivation 
of receptor tyrosine kinases by adenosine 2A receptors 
[9, 10], pituitary adenylate cyclase-activating polypeptide 
receptor [11], low-density lipoprotein receptor-related 
protein 1 [12], epidermal growth factor receptor [13] and 
antidepressants [14].
Human TRKA gene is located on chromosome 1 and 
has been described to span 23  kb. Seventeen exons 
(named 1…17; Fig.  1), that are relatively well conserved 
in rat and mouse as compared to human TRKA gene, 
[the basic local alignment search tool (BLAST) algorithm 
gives 85 % of similarity in both cases] have been charac-
terized [15–17].
The extracellular portion of TRKA receptor, coded by 
exons 1–10, is responsible for ligand binding and is sub-
jected to post-translational glycosylation. A sequence 
coded by exon 1 directs the receptor to the cell mem-
brane. The predominant part of the extracellular region 
constitutes of the first and second immunoglobulin-like 
(Ig-like) domains coded by exons 6…8, of which the sec-
ond is directly in contact with NGF [18]. The transmem-
brane domain of TRKA is encoded by exon 11 and the 
intracellular tyrosine kinase domain by exons 13…17 [19, 
20].
The glycosylation of the receptor’s extracellular seg-
ment plays an important role in signaling and localiza-
tion of the protein. There are four N-glycosylation sites 
that are highly conserved within the TRK family and at 
least five more variable sites that are used in TRKA. The 
lack of glycosylation results in autophosphorylation and 
constitutive kinase activity of the core protein as well as 
incapability to be directed to the cell membrane [21, 22].
TRKA gene is a target of alternative splicing which 
can result in several different protein isoforms. At the 
moment, only three human isoforms (TRKAI, TRKAII 
and TRKAIII) and two additional rat isoforms (TRKA 
L0 and TRKA L1) have been described. TRKAII is the 
full-length isoform. In mRNA encoding TRKAI an 18 bp 
exon 9 has been spliced out resulting in a protein lacking 
6 aa in the juxtamembrane region of the TRKA receptor. 
The full-length TRKAII is mainly expressed in neuronal 
tissues and TRKAI in non-neuronal tissues. They appear 
to have no relevant difference in binding to NGF [23]. 
In contrast, binding to NT-3 is significantly stronger in 
the case of TRKAII compared to TRKAI [24]. The third 
alternatively spliced transcript TRKAIII is lacking exons 
6, 7 and 9. This results in the absence of the first immu-
noglobulin-like domain and several N-glycosylation sites. 
As a consequence, TRKAIII is not able to bind NGF and 
is instead constantly autophosphorylated and activated. 
Alternative splicing of TRKA mRNA to generate the 
isoform TRKAIII is upregulated by hypoxia. TRKAIII 
is expressed in undifferentiated early neural progeni-
tors, in a subset of neural crest-derived tumors (nota-
bly in neuroblastomas) and in thymus, a physiologically 
hypoxic organ [25, 26]. Unlike TRKAI/II, this isoform is 
not inserted in the plasma membrane, but is retained in 
endoplasmatic reticulum (ER) and Golgi complex and 
promotes genetic instability [27]. In rats, similarly to 
humans, exon nine can be spliced out [23]. In addition, 
rat splice variants termed TRKAL1 and TRKAL0 lack 
respectively either two of the leucine-rich motifs or all 
three [28]. Isoforms of TRKA in mouse have not yet been 
described.
A genetic disorder congenital insensitivity to pain with 
anhidrosis (CIPA), also called hereditary sensory and 
autonomic neuropathy type IV, has various symptoms 
such as absence of reaction to noxious stimuli (insensitiv-
ity to pain), anhidrosis (inability to sweat), self-mutilat-
ing behavior and mental retardation. CIPA is caused by 
non-functional or absent TRKA receptor due to muta-
tions in TRKA gene [29]. On the other hand, excessive 
NGF-TRKA signaling hypersensitizes pain-mediating 
neurons resulting in chronic pain [30] or causes aller-
gic skin inflammation [29], hyper-responsiveness of air-
way epithelial cells and/or aberrant activation of sensory 
(See figure on next page.) 
Fig. 1 Human TRKA gene locus and predicted protein isoforms of human, rat and mouse TRKA. Exons are illustrated as boxes and introns as lines. 
Exons are drawn to scale in a–f and introns in a. a Chromosomal organization of the human TRKA gene. Also shown are two genes encoded from 
the opposite strand and partially (SH2D2A) or entirely (INSRR) overlapping the TRKA gene. b All human TRKA exons with size in bp-s shown in dark 
pink. Representational scheme of TRKA alternative transcripts and putative protein isoforms of human (c and d), mouse (e) and rat (f) origin, based on 
the results of 5′ RACE, RT-PCR study and in silico analysis. The names of encoded proteins are noted on the right. Alternative N-termini as compared 
to the conventional TRKAII isoform are labeled as α, β, γ, δ, ε, ζ, η, θ, κ, λ, μ and ξ. Only one ORF per transcript has been marked with start site (blue 
arrowhead) and stop codon (red asterisk). Roman numerals designate protein isoforms missing various parts of the extracellular region as illustrated 
for TRKAI…TRKAIX d. Exons 10a and 9a can either serve as 5′ exons or be the products of intron retention (due to this, the block of exons upstream 
of exons 10a and 9a is illustrated in gray). ARF alternative reading-frame. The L0 isoform of rat TRKA is produced from transcripts that do not include 
exons 2–4 and L1 from mRNAs missing exons 2 and 3. g the protein domains of TRKAII (MSS membrane signal sequence, Cys and Leu rich region 
cysteine and leucine rich region, IG like immunoglobulin-like domain, TM transmembrane)
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neurons, implicated in acute conditions such as asthma 
[31].
Alterations in TRKA expression or mutations in the 
gene have been detected in several tumors. TRKA was 
discovered as an oncogene in colon carcinoma fused 
with tropomyosin gene [32]. Genomic DNA rearrange-
ments of TRK genes can influence carcinogenic progres-
sion in non-neuronal tissues such as breast cancer [33], 
papillary thyroid carcinoma [34] and medullary thyroid 
carcinoma [35]. In neuroblastomas, TRKA upregulation 
is seen in tumors with good prognosis, while TRKB is 
up-regulated in unfavorable and aggressive tumors [36]. 
However, TRKA can also be involved in the late stages of 
cancer progression by promoting stress-resistance and 
neovascularization—for example in neuroblastomas by 
TRKAIII isoform [37]. During the progression of Alz-
heimer’s disease, all TRK receptors are down-regulated 
in cholinergic neurons of nucleus basalis, a brain region 
which dysfunction is associated with cognitive decline 
in Alzheimer’s disease [38]. The cholinergic neurons 
depend on NGF which is synthesized by the target cells 
within the hippocampus and cortex. TRKA expression 
is also decreased in the parietal cortex of patients with 
Alzheimer’s disease [39, 40]. Moreover, the withdrawal of 
NGF in differentiated rat pheochromocytoma PC12 cells 
initiates the accumulation of beta-amyloid protein and is 
followed by apoptotic death [41].
In this study, we show that the TRKA gene in rat, 
mouse and especially human is more complex than previ-
ously thought. We also show that the human TRKA has 
multiple 5′ terminal exons and an intricate splicing pat-
tern involving exons that encode the extracellular part of 
TRKA protein. It can be theorized that these novel TRKA 
transcripts encode numerous TRKA protein isoforms 
which have not yet been characterized.
Results
An elaborate arrangement of the human TRKA gene 
revealed by novel transcription initiation sites
In silico analysis of the human TRKA gene structure 
using UCSC genome browser [42] to align the TRKA 
mRNAs and expressed sequence tags (ESTs) from Gen-
Bank to the genomic sequence indicated a higher level of 
variability among TRKA transcripts and a longer span of 
the gene than previously described in the literature. For 
this reason, we performed reverse transcription polymer-
ase chain reaction (RT-PCR) and rapid amplification of 5′ 
complementary DNA ends (5′ RACE) analyses to better 
describe TRKA gene and its transcripts. In the RT-PCR 
study, we used a selection of adult and fetal tissues and 
different regions of the nervous system. Also included 
were neuroblastoma cell-lines SH-SY-5Y and SK-NMC 
which are known to express TRKA. Total RNA from SH-
SY-5Y neuroblastoma cells and thalamus were used in 
5′ RACE experiments as these tissues showed relatively 
high levels of TRKA expression in our preliminary exper-
iments. From the information obtained of mRNAs, we 
predicted potential TRKA protein isoforms and named 
them in this study as follows: isoforms with different 
N-termini from the conventional TRKAII are named as 
α, β, γ, δ, ε, ζ, η, θ and κ (Fig.  1c), isoforms which lack 
different parts in their extracellular portion are distin-
guished with roman numerals I…IX (Fig.  1d; protein 
sequences are listed in Additional file 1).
We detected multiple transcription start-sites in exon 
1, most of which are located upstream of the conven-
tional translation start-site in the position 156860935 nt 
of the GRCh38 human genome assembly (Fig. 2). How-
ever, there is an additional in-frame ATG in the position 
156860857 nt that was included in some forms of exon 1 
(named in this study as 1a). If this AUG is sterically acces-
sible for the ribosome, an N-terminally elongated protein 
(named here as TRKAα) compared to the conventional 
TRKAII would be produced. On the other hand, some 
transcripts had a shorter exon 1 (exon 1b) with no in-
frame AUG codons. Translation from mRNAs with exon 
1b probably starts from the next in-frame AUG which is 
in exon 5 (in genomic position 156868231 nt) creating 
TRKAε. The online transmembrane topology and signal 
peptide predictor Phobius [43] predicts no membrane 
signal sequences for TRKAα or TRKAε.
Analysis of GenBank sequences [GenBank:DA013446, 
GenBank:DB265639, GenBank:AK126428] revealed the 
presence of a novel 5′ terminus of TRKA mRNAs formed 
by alternative transcription initiation and usage of four 
novel exons that are in this study termed as A, B, C and D 
(See figure on next page.) 
Fig. 2 The human TRKA gene has numerous transcription start sites producing more alternative 5′ exons than mouse and rat TrkA genes. Results of 
the 5′ RACE analysis of TRKA mRNA of human (combined results of extracts from thalamus and SH-SY-5Y cell line), mouse (brain at embryonic day 13) 
and rat (PC12 cell line). Novel transcription start-sites are indicated in blue bold letters and marked with a blue arrow head. Transcription initiation sites 
deduced from GenBank sequences of previously described mRNAs and ESTs that are obtained with 5′ RACE analysis are displayed in bold underlined 
letters and designated with black asterisks with the corresponding GenBank accession numbers shown. Red and bold letters indicate alternative puta-
tive translation start sites with the conventional translation initiation site (producing TRKAII protein isoform) underlined. The translational start site 
from alternative reading frame that is used if exons 2…9 are spliced out in human tissues between exons 1 and 10 is indicated in pink bold letters. 
Exons are marked with grey background. The numbering is based on the human genome assembly GRCh38 (hg38), the mouse genome assembly 
GRCm38 (mm10) or the rat genome assembly RGSC6.0 (rn6)
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(Fig. 1). We confirmed with 5′ RACE using mRNAs from 
adult human thalamus that exon A serves as a transcrip-
tional start-site (Fig. 2). Exon A is located approximately 
45 kb upstream of exon 1 and therefore the size of TRKA 
gene is 67  kb—almost three times bigger than previ-
ously thought. It is of interest to note that exon A is in 
the intron between the second and the third exon of sar-
coma protein homology 2 domain protein 2A (SH2D2A) 
gene that is encoded on the complementary strand from 
TRKA. The transcription start sites of these genes are in a 
head-to-head orientation and lie less than 1 kb apart. On 
the same strand and upstream from SH2D2A gene, there 
is insulin receptor-related protein (INSRR) gene which 
is completely embedded into TRKA gene (Fig. 1a). Thus, 
TRKA is overlapped by two genes and that is rather unu-
sual according to Veeramachaneni and associates, who 
identified only 18 overlapping gene trios in the human 
genome [44]. Transcription start sites of TRKA exon 1 
and INSRR gene are in a nearby head-to-head orientation 
and are less than 2 kb apart. TRKA exon D and a coding 
exon in INSRR gene overlap by more than 80 bp.
Translation of transcripts with exons A and D fol-
lowed by exons 2, 3, etc., starts most probably from an 
AUG near the end of exon A (from the genomic posi-
tion 156815830 nt) producing TRKAγ. Besides this major 
ORF, these transcripts also have many small upstream 
ORFs (uORFs) in different reading-frames that are 
no bigger than 111 nt. For mRNAs with exons A-C-D 
or A-B-C-D, the primary ORF starts in exon D (from 
genomic position 156842144 nt) generating TRKAδ. 
uORFs of these transcripts are longer, reaching 336 nt. 
Phobius predicts membrane signal sequence for TRKAγ 
but not for TRKAδ.
Using 5′ RACE analysis, we also identified novel exons 
E, G and 11a as alternative TRKA 5′ exons (Fig. 2). Exon 
E is located 1.5  kb upstream of exon 1 and may be fol-
lowed by novel exon F which has three alternative 3′ ter-
mini (generating Fa, Fb and Fc exon variants). Exon E is 
even closer to the INSRR gene than exon 1, but does not 
overlap with it. RT-PCR also revealed two novel exons 
located downstream of exon 3 that are named in this 
study as 3a and 3b that can be spliced into mRNAs with 
5′ exons E and Fa (Figs. 1b, 3). Exon G is located between 
exons 1 and 2, specifically 2.3 kb downstream of exon 1, 
and has alternative versions Ga, Gb, Gc and Gd that dif-
fer from each other in both 5′ and 3′ splice sites (Fig. 2). 
Using RT-PCR we also detected intron retention between 
exons G and 2 generating an extended exon that is here 
named as 2a. The major ORF of mRNAs with exons E, F, 
G and 2a is located to exons 5…17 and encodes TRKAε. 
All of these mRNAs have 1…3 uORFs in alternative read-
ing frames that are less than 168 nt, with the exception of 
transcripts that start with exon 2a in which case there are 
18 uORFs with a maximum length of 321 nt.
The 5′ exon 11a is located 95 bp downstream of exon 10 
and transcripts with this exon encode for TRKAθ which 
has no predicted membrane signal sequence. The first 
ATG is located near the 3′ end of exon 11a at genomic 
position 156874785 nt. There are no uORFs on these 
mRNAs.
The exon complexes A…D and E–F and exons 1, G, 2a 
and 11a are all mutually exclusive as we didn’t observe 
any transcripts with different combinations of these 5′ 
exons or exon complexes.
Surprisingly, we also detected transcription initiation 
from exon 10 and from many different nucleotides within 
exon 8 (Fig. 2). Most of the mRNAs that have exon 8 as 
the 5′ exon contain in-frame AUG codons present near 
the 3′ end of exon 8 (this variant of the exon is named 
in here as 8b). Assuming that the first of these codons 
(at genomic position 156873905 nt) serves as a transla-
tional start-site, the protein produced is TRKAη. These 
transcripts have no uORFs. TRKA transcripts that start 
with exon 8c that is shorter than 8b, which contains no 
in-frame AUG codons, or with 10b have a major ORF 
situated in exons 12…17 with the first ATG in genomic 
position 156875555 nt and encoding TRKAκ protein iso-
form. 2 uORFs with a maximum length of 171 nt are also 
present.
According to one EST and our 5′ RACE results, tran-
scription can also start in the intron between exons 8 
and 9, from exon 10a which contains exons 9 and 10 and 
the intron between them (Fig. 2). With RT-PCR we also 
detected the presence of exon 9a that is similar to exon 
10a, but its 3′ end coincides with the one in exon 9 (the 
intron between exons 9 and 10 is spliced out in this case). 
With RT-PCR (data not shown) we detected the presence 
of exons 9a and 10a in transcripts that have additional 
exons in 5′ direction and in that case exons 9a and 10a 
are the products of intron retention as they span from the 
5′ end of exon 8 to the 3′ end of exon 9 or 10, respec-
tively. In either case, there are multiple ORFs in these 
transcripts, but the ORF that extends into the 3′ exons 
and which translation would salvage these mRNAs from 
nonsense mediated decay (NMD), encodes for TRKAκ 
protein isoform. However, the true functionality of these 
transcripts is presently unknown.
Human TRKA exons 2…9 encoding the extracellular 
domain are all cassette exons with an intricate splicing 
pattern
Several exons of the human TRKA gene can be spliced 
out. All of these encode parts of the extracellular domain 
of TRKA protein. The splicing of cassette exon 9 has been 
Page 7 of 21Luberg et al. BMC Neurosci  (2015) 16:78 
described and the protein isoform encoded by exons 
1…17 is known as TRKAII and the exclusion of amino 
acids encoded by exon 9 leads to the production TRKAI 
protein isoform [23]. Formerly, exclusion of exons 6, 7 
and 9 from TRKA mRNA has also been reported, giv-
ing rise to a protein isoform TRKAIII [25]. We detected 
alternative splicing of all exons encoding the extracellular 




































































































































































































































































































































Fig. 3 Semi-quantitative analysis of TRKA transcripts by RT-PCR in different human, mouse and rat tissues, in human neuroblastoma SH-SY5Y and 
SK-NMC cells and in rat pheochromocytoma PC12 cells. The exons present in the PCR products are marked on the left. Hypoxanthine guanine phos-
phoribosyltransferase (HPRT) gene specific primers were used for the housekeeping control. E13 samples from brain at embryonic day 13, P1, P7, P9, 
P14, P21 and P60 samples from brain at postnatal days 1, 7, 9, 14, 21 and 60, respectively
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3). Additionally to the mRNA isoforms described previ-
ously, alternative splicing that does not disturb the read-
ing frame of transcripts was detected as the exclusion 
of exon complexes 6-7 (producing TRKAIV), 6-7-8-9 
(TRKAV), 8-9 (TRKAVI) and 2-3-4-5. In the latter case, 
alternative splice sites are used for exons 1 and 6 result-
ing in exons 1c (20 nt shorter from the conventional exon 
1 from the 3′ end) and 6c (113 nt shorter from exon 6 
from the 5′ end). The protein encoded by transcripts 
with exons 1c-6c-7…17 is TRKAVII. Theoretically, the 
same splicing patterns can also be present in transcripts 
with other 5′ termini and thus, the putative protein iso-
forms of human TRKA also include TRKAαI, TRKAαII, 
TRKAγI, etc.
Moreover, there are many splice forms that produce a 
frame-shift. This includes transcripts with exons 6a-10 
and 6a-9-10 and lacking exons 7 and 8 (and 9 in the for-
mer case; Fig.  1c) as identified with 5′ RACE analysis. 
Exon 6a is a shorter version of exon 6 with 17 nt missing 
from the 5′ end as compared to exon 6. The sequence of 
exon 6a is read in an alternative reading frame, produc-
ing isoforms TRKAVIII and TRKAIX, respectively. Alter-
native reading-frame of exon 1 is most probably used 
with transcripts which are missing the complex of exons 
2…9, generating TRKAβ which lacks membrane signal 
sequence according to Phobius program. Translational 
start-site most probably used in this case is located 100 nt 
from the 3′ end of exon 1 (at genomic position 156861047 
nt). One uORF of 294 nt is present in that mRNA.
One of the many types of human TRKA transcripts 
identified with RT-PCR contained exons 1d-6b-7-8a with 
exons 2…5 spliced out. Exon 1d is 122 nt shorter from 
exon 1 from the 3′ terminus, exon 6b is 83 nt shorter 
from exon 6 from the 5′ end, and 8a is an extended form 
of exon 8 with additional 137 nt in its 5′ terminus. This 
mRNA most probably encodes for TRKAζII with the 
translational initiation site in exon 8 (at genomic position 
156873668 nt) although it has 4 uORFs with the maxi-
mum length of 297 nt. TRKAζII possesses no predicted 
membrane signal sequences.
With RT-PCR we identified the exclusion of exon 7 or 
exon complexes 2…6, 2…7, 5-6, 5…7, and 7…9 that also 
produce frame-shifts. To escape the NMD pathway, the 
ORF expressed from these transcripts should encode 
TRKAκ (in case exons 7-8-9 are spliced out) or TRKAζI/
TRKAζII (in case of other splice-combinations). How-
ever, all these mRNAs contain uORFs that are in some 
cases rather large. Therefore, the exact function (if any) of 
these transcripts is uncertain.
With primers located in TRKA exons C and 5 two PCR 
products with similar lengths (cDNA from frontal cer-
ebral cortex, Fig.  3) were identified with sequencing. It 
appeared that the longer product contained an extended 
form of exon 2 with additional 22 bp in its 3′ end (that we 
named 2b) compared to the normal exon 2. This induces 
a frameshift and results in a premature stop codon. To 
escape the NMD pathway, the protein translated from 
that transcript should be TRKAε, regardless of multiple 
uORFs with maximum length of 189 nt.
TrkA alternative transcripts lacking exons 2…3 
(TrkAL1) or exons 2…4 (TrkAL0) have been found in 
Wistar rats [28]. However, we did not detect such tran-
scripts of human TRKA gene, suggesting that these tran-
scripts might be rodent-specific.
Expression pattern of TRKA transcripts in human tissues 
and cell‑lines
Next, we wanted to elucidate the expression pattern of 
TRKA transcripts in different tissues. To this purpose, 
we examined TRKA transcript expression with RT-PCR 
analysis in a selection of human tissues, brain regions and 
two neuroblastoma cell-lines. The results (Fig.  3) indi-
cated that transcripts with 5′ exons A-D were expressed 
in most examined tissues, except in adult testis and fron-
tal cerebral cortex as well as fetal frontal lobe. Expres-
sion of this transcript was also seen in neuroblastoma 
SH-SY5Y cells, but not in neuroblastoma SK-NMC cells. 
Transcripts with exons A-C-D were widely expressed 
in different tissues apart from adult testis, fetal dien-
cephalon, cerebellum and lung, and SK-NMC cells. The 
rare splice variant with exons A-B-C-D was expressed 
at very low levels in several tissues, more significantly in 
adult frontal lobe, corpus callosum, and spleen as well as 
in fetal spinal cord. The expression of exon 2b was even 
rarer, as we detected it only in frontal cerebral cortex.
The transcript including exons D and 8, and exclud-
ing exons 2…7 had a wide expression pattern with the 
exception of adult parietal lobe and with relatively higher 
expression in SH-SY-5Y cells and adult prostate and thy-
mus. The expression of mRNAs with exons D-7-8 with an 
absence of exons 2…6 was not unanimous and displayed 
higher levels in adult corpus callosum, muscle, heart, tes-
tis and colon, fetal cerebellum, heart and spinal cord, and 
SH-SY-5Y cell line. Human TRKA transcripts with exons 
D-2-3-4-5-6-8 (missing exon 7) and D-2-3-4-8 (missing 
exons 5-6-7) were expressed in low levels in all studied 
tissues except adult parietal lobe and the SK-NMC cell 
line. We did not observe mRNAs with exons D-2-3-4-5-
6-7-8 in adult cerebellum, testis and spleen, fetal lung and 
SK-NMC cells. The highest expression of these mRNAs 
was found in adult amygdala, thalamus, muscle and 
thymus.
Exon complex 1…8 was detected in mRNAs from all tis-
sues studied, with especially high levels in adult amygdala, 
thalamus, prostate, kidney and thymus, fetal diencephalon, 
heart and spinal cord and SH-SY-5Y cells. mRNAs with 
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exons 1c-6c-7-8 were detected in low levels in adult fron-
tal and parietal lobe, amygdala, muscle, testis and colon 
and neuroblastomas. Relatively low levels of transcripts 
with exons 1-2-3-4-5-6-8 (with exon 7 spliced out), 1-2-3-
4-7-8, 1-2-3-4-8 and/or 1d-6b-7-8a that are all encoding 
the TRKA ζ isoform, were observed in all tissues analyzed 
with the exception of adult parietal lobe, frontal cerebral 
cortex and cerebellum. The expression of transcripts with 
exon 1 and 8 (missing the cassette of exons 2…7) was high-
est in SK-NMC cells, testis and fetal cerebellum, and below 
detection limit in adult occipital lobe, cerebellum, muscle, 
prostate, pancreas, kidney and spleen.
Novel 5′ exons E, F and G were expressed in many 
tissues with the highest levels in cerebellum, neuro-
blastomas, testis, colon, thymus and fetal frontal lobe, 
diencephalon, lung, muscle and spinal cord. Adult frontal 
cerebral cortex, corpus callosum, pancreas and fetal heart 
were the tissues where expression of these exons was 
below the detection limit. Exon 2a was expressed in only 
a small selection of tissues, most notably in frontal lobe, 
cerebellum and kidney.
Splicing in the region of exons 6…8 was a rare event 
with the highest prevalence of transcripts lacking exon 7 
or exons 7…9. Splice forms where exons 8-9, 6-7-8-9 or 
6-7 are spliced out appeared to be neuroblastoma spe-
cific, as they were detected only in the samples from SH-
SY5Y and SK-NMC cells. These mRNAs encode TRKA 
proteins without one or two Ig-like domains.
The transcript containing exon 9 is predominately 
expressed in neural tissues while the exclusion of exon 9 
has been observed in peripheral tissues [23, 24]. In that 
respect, the results of this study are in accordance with 
previous findings. In some tissues, such as adult prostate, 
fetal diencephalon and heart as well as in neuroblastoma 
SH-SY5Y, both of the transcripts were detected.
Transcripts with exon 10a were detected in many tis-
sues with the exceptions of SK-NMC cells, adult heart, 
pancreas and spleen. The novel exon 9a was expressed 
at minute levels in frontal lobe, occipital lobe, amygdala, 
thalamus, muscle, testis, fetal diencephalon and spinal 
cord and neuroblastoma cells.
We failed to design PCR primers with which it would 
be possible to amplify TRKA sequences with exon 11a. 
Most probably the expression level of these transcripts is 
very low.
All analyzed TRKA transcript variants shared com-
mon 3′ exons as we did not detect any alternative splicing 
after exon 11. Therefore, the expression pattern of exons 
12…17 corresponded to TRKA mRNA overall levels and 
was the highest in adult amygdala, thalamus, testis, neu-
roblastomas and in fetal diencephalon and spinal cord 
according to PCR results with primers targeting exon 12 
and 17 (Fig. 3).
Mouse and rat TrkA mRNAs display smaller variability 
than human TRKA transcripts
To examine whether the complex splicing pattern seen 
in human tissues is conserved in other mammals, mouse 
and rat samples were also analyzed. Rat and mouse tis-
sues to be examined were chosen according to previ-
ous results in human and taking into consideration the 
tissue and/or mRNA availability. Rat PC12 cell line was 
included in the rat expression panel as it has been shown 
to express high levels of TrkA and has been the major 
tool to perform research on TRKA receptor, including 
this study [45].
Total RNA isolated from mouse brain E13 tissue and 
rat PC12 cells was used in 5′ RACE experiments as these 
tissues showed relatively high levels of TrkA expres-
sion. Our 5′ RACE results and a few mouse sequences 
in public databases indicated that most often transcrip-
tion is initiated from exon 1 upstream of the conven-
tional translation-start site at position 87795144 of the 
GRCm38 mouse genome assembly and at 187160312 of 
the RGSC6.0 rat genome assembly (Fig. 2). However, we 
detected rat TrkA mRNAs that have 5′ end in exon 1, but 
downstream of this AUG. This variant of exon 1 is named 
here as 1b and the major ORF of rat TrkA transcripts con-
taining exon 1b starts from exon 6 at genomic position 
187153794 and encodes TRKAμ protein (Fig. 1f ). Three 
small uORFs with length up to 63 nt are also present.
A sequence in GenBank [GenBank:AK148691], that 
has been obtained by 5′ RACE, and also sequences from 
our 5′ RACE results additionally characterize both mouse 
and rat TrkAs with 5′ termini inside exon 8 (named in this 
case as 8d or 8b, for longer and shorter versions, respec-
tively). These transcripts encode TRKAλ and TRKAη 
proteins, both of which have translation-initiation sites 
in exon 8: TRKAλ at genomic position 87783826 (mouse) 
or 187149147 (rat), and TRKAη at position 87783724 
(mouse) or 187149045 (rat). Mouse and rat transcripts 
with 5′ exons 8d and 8b have uORFs up to 282 nt, with 
the exception of mouse mRNAs with exon 8b, which 
have no uORFs.
Similarly to human mRNA, we also identified tran-
scription initiation from within TrkA exon 10 (named in 
that case as 10b) in mouse mRNA, but not in rat mRNA. 
Translation from mouse TrkA mRNAs with 10b as 5′ ter-
minus most probably starts from exon 12 (at genomic 
position 87782262) producing TRKAκ protein, similarly 
to the human orthologue. 3 uORFs up to 114 nt are also 
present.
We did not observe 5′ exons of rat or mouse TrkA alter-
native to exon 1, 8 or 10 and PCR with primers designed 
based on sequence similarities with human exons A and 
D did not give any results in samples from either mouse 
or rat tissues. TrkA genes of mouse and rat therefore 
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do not overlap with either SH2D2A or INSRR genes, 
although the latter one is very close to TrkA exon 1 in 
case of both species.
Analysis of TrkA transcripts in mouse and rat revealed 
that both express exons 9a and 10a and therefore, poten-
tially also TRKAκ (Fig. 1e, f ). As we did not detect exons 
9a or 10a in 5′ RACE experiments using mouse or rat 
samples, it can be concluded that these exons are pro-
duced in these animals only by intron retention and not 
by alternative transcription initiation mechanism seen 
in human. In case of rat transcripts with exon 10a, the 
potential translational start-site is most probably located 
in the intron between exons 9 and 10 and TRKAξ protein 
is generated (Fig.  1f ). However, mouse and rat mRNAs 
with exons 9a or 10a have many uORFs, some of which 
are very large.
Furthermore, exon 9 is a cassette exon in both mouse 
and rat and exon 11 can be spliced out in mouse. While 
the splice variants lacking exons 2 and 3 or exons 2…4 
have been described in literature, we identified only the 
latter one [28].
A membrane signal sequence was not detected by 
Phobius prediction tool for any novel putative TRKA 
isoforms in rat or mouse with N-termini other than the 
conventional Met of TRKAI/TRKAII.
Expression of TrkA mRNAs in mouse tissues
The expression of TrkA mRNA was studied in a selec-
tion of adult neuronal and non-neuronal tissues as well 
as in developmental samples from mouse brain at ges-
tation day 13 (E13) and at postnatal days 1, 9, 14 and 
60 (P1, P9, P14 and P60, respectively; Fig.  3). Accord-
ing to the expression level of exons 12…17, common to 
all possible splice forms, the samples examined showed 
relatively similar overall TrkA expression levels with 
the exception of muscle tissue, where TrkA mRNA was 
almost undetectable. The 5′ region of transcripts from 
heart sample was identified only when the number of 
PCR cycles was increased (data not shown). The devel-
opmental tissues analyzed had a fairly higher expression 
level of TrkA.
In human and rat TRKA transcripts, exon 9 was 
spliced out in non-neuronal tissues and included in neu-
ronal tissues. In mouse, this rule seems not to apply, 
as TrkA mRNAs without exon 9 were observed only in 
testes as a minor product in addition to the major form 
with exon 9.
Interestingly, PCR with primers amplifying exons 10a 
and 9a predominately gave rise to products with exon 9a 
not with 10a, which is in contrast to our results in human 
and rat tissues. It can be concluded that the regulation of 
splicing in the region around exon 9 of the TrkA mRNA 
in mouse is different from that in rat and human.
Furthermore, a splice form lacking exon 11 was 
detected in mouse testis sample only when exon 9a was 
included in the transcript.
Analysis of mouse samples provided evidence that 
alternative transcription initiation and splicing of TrkA 
gene is less complex in mouse than in human. How-
ever, a novel splice form, lacking exon 11 and not seen 
in human, was identified. TrkA expression in muscle was 
almost undetectable in mouse while the overall level of 
TRKA in human muscle tissue was not significantly lower 
than in other tissues.
Expression of TrkA mRNAs in rat tissues
TrkA expression was detected in all rat tissues analyzed 
(Fig. 3). The overall mRNA levels were higher in develop-
mental brain samples [embryonic day (E) 13, postanatal 
day (P) 7 and P21], in adult whole brain and sympathetic 
ganglia and in PC12 cell line, and lowest in heart.
Splice variant lacking exons 2 and 3 was detected in 
minor quantities in PC12 cells. TrkA transcript, where 
exon 9 has been spliced out, was observed in kidney, tes-
tis, muscle, heart—the analyzed non-neuronal tissues, 
and also in the PC12 cells. In the rest of the samples and 
also in testis and PC12 cells, the major transcript con-
tained exon 9. The splicing pattern of TrkA exon 9 in dif-
ferent rat tissues was similar to human, but different from 
mouse.
Similarly to human, transcripts with exon 10a were 
more frequent than transcripts with exon 9a, with the 
exception of adult whole brain and sympathetic ganglia. 
In cortex and in P21 brain, neither was detected. Yet in 
most of the other neuronal tissues and in PC12 cells, 
both transcript variants were observed. Interestingly, the 
expression levels of transcripts with exons 10a and 9a 
were fluctuating during the development: in embryonic 
brain from gestation day 13, a relatively high level of tran-
scripts with 10a exon was observed as well as relatively 
low levels of 9a variant. Thereafter, the level of these 
mRNAs started to decrease, as P7 brain had lower lev-
els of these splice variants and at P21 the signal of TrkA 
mRNAs with exons 10a or 9a was not detected. However, 
the transcript with exon 9a was observed again in the 
adult whole brain.
Interestingly, the expression of TRKA in human and rat 
muscle tissues followed a similar pattern while in mouse 
it was undetectable. Heart displayed contrary expression 
profiles by having relatively low TRKA transcription lev-
els in human and rat and higher levels in mouse.
Endogenous TRKA protein isoforms in PC12 and SH‑SY5Y 
cells
To examine the expression of TrkA on protein level, PC12 
cell line from rat was chosen for the experiments as it has 
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been used widely for research on TRKA. Of TRK recep-
tors, it is known to express predominantly TRKA and 
to be NGF responsive [45]. The SH-SY5Y cell line was 
added to analyses as it showed the highest levels of TRKA 
mRNA expression among human samples in the RT-PCR 
studies.
We tested many antibodies and according to results 
obtained with siRNA treated PC12 cell lysates, the most 
effective antibody to detect the low levels of endogenous 
TRKA was an anti-TRKA rabbit polyclonal antibody by 
Millipore (#06-574, see also “Methods”). The epitope 
of this antibody localizes to the extracellular region of 
TRKA protein, consequently it would not be able to rec-
ognize several putative isoforms excluding this region. 
Another promising antibody was an anti-TRK rabbit 
monoclonal antibody by Cell Signaling (#4609, see also 
Methods), which recognizes all three TRK receptors 
and has its epitope around Y785 of TRKA C-terminus. 
Lastly, we also used an anti-pTRKA antibody from Cell 
Signaling (#9141, see also “Methods”) that only recog-
nizes phosphorylated TRK proteins. 5  min NGF treat-
ment before the lysis of the cells was used to activate the 
intrinsic phosphorylation ability of TRKA proteins. Both 
anti-TRK and anti-pTRKA antibodies are therefore pre-
sumably capable of distinguishing all putative TRKA iso-
forms that contain the kinase domain.
In PC12 cells the full-length TRKAI/TRKAII protein of 
≈100 kDa and it’s glycosylated forms ≈120 and 140 kDa 
were detected by both anti-TRK (#4609) and anti-TRKA 
(#06-574) antibodies (Fig.  4a). Using anti-TRK (#4609) 
antibody the signal from smaller proteins than 100 kDa 
was not observed. Similarly, the anti-pTRKA (#9141) 
antibody detected only the full-length pTRKAI/pTRKAII 
in its glycosylated form (≈140 kDa; Fig. 4b) which is the 
type of TRKA expressed on the cell surface and is there-
fore accessible to extracellular NGF. In our current study 
we were not able to distinguish with the given antibodies 
in PC12 cells the predicted novel TRKA isoforms. This 
could be caused by the poor ability of antibodies to rec-
ognize low levels of endogenous TRKA.
In SH-SY5Y cells the signals corresponding to 120 and 
140  kDa probably represent the differently glycosylated 
TRKA proteins. The anti-pTRKA antibody did not detect 
signals from SH-SY5Y cell lysates even if the cells had 
been previously treated with NGF (data not shown) sug-
gesting that TRKA receptors are not functional in prolif-
erating SH-SY5Y cells used for analysis.
Interestingly, by all three antibodies used a ~180  kDa 
signal was detected, which identity remains to be eluci-
dated. If this is indeed TRKA, e.g., a very stable hyper-
glycosylated form, it appears to be a type that does not 
respond to NGF treatment (Fig. 4b).
TRKAII putative isoforms differ in autocatalysis rate
We were next interested in describing novel putative 
TRKA isoforms in more detail. Most of the detected 
human TRKA transcripts have out of frame uORFs 
relative to the ORF that is depicted in Fig.  1c. None of 
these uORFs reach the 3′ exons of TRKA. Due to this, if 
the longest ORF is not translated, the mRNA would be 
subjected to NMD, a process which promotes the deg-
radation of mRNAs undergoing premature translation 
a b
Fig. 4 Detection of endogenous TRKA protein in human SH-SY5Y and rat PC12 cell line. a 50 µg of lysates of PC12 cells transfected (48 h) with 
siRNAs and SH-SY5Y cells was separated on SDS-PAGE. Western blot analysis was performed using Cell Signaling anti-TRK [epitope in the intracel-
lular region (ICD) of TRK proteins; #4609] and Millipore anti-TRKA [epitope in the extracellular region (ECD); #06-574] antibodies. b PC12 cells were 
transfected (48 h) with siRNAs and treated for 5 min with NGF. Mock-treated cells were used as control. 60 µg of lysates was subjected to SDS-PAGE 
and western blotting with antibody against phosphorylated TRKA (Cell Signaling anti-pTRKA; #9141). GAPDH was used to validate the loading 
efficiency. siScr unspecific scrambled siRNA, siTRKA rat TRKA specific siRNA, neg mock treated cells
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termination. We hypothesized that these transcripts 
might undergo leaky scanning or reinitiation that would 
exclude them from NMD as the uORF sequences start 
with AUG surrounded with weak Kozak sequences [46].
TRKA isoforms with different N-termini can each 
have several splice forms (except TRKAβ, TRKAθ and 
TRKAκ); however, the functional implications of the 
exclusion of six amino acids encoded by exon 9 (resulting 
in TRKAI, TRKAαI, TRKAγI, etc.) have been described 
before [23, 24]. Also, transcripts encoding TRKA iso-
forms other than type I and II showed relatively low level 
of expression. Accordingly, TRKA isoforms of type I, 
III, IV, V, VI, VII, VIII and IX were omitted from further 
analysis for simplicity.
To determine whether N-terminal differences of puta-
tive TRKA isoforms influence autophosphorylation 
capacity, a selection of potential TRKA isoforms was 
cloned and the expression constructs of TRKAII-V5-His, 
TRKAγII-V5-His, TRKAδII-V5-His, TRKAεII-V5-His, 
TRKAζII-V5-His and TRKAκ-V5-His were transfected 
into human embryonic kidney 293 cells (HEK293), fol-
lowed by lysis and V5-tag-aimed immunoprecipitation 
to eliminate endogenous phospho-tyrosine (pY)-proteins 
from Western blot analysis. Total precipitated protein 
was visualized with an antibody against V5-tag and phos-
phorylated subportion with anti-pY antibody. All iso-
forms were expressed efficiently (Fig. 5a, left panel) and 
displayed catalytic activity (Fig.  5a, right panel). It was 
repeatedly observed that TRKAκ-V5-His immunopre-
cipitate contained pY-proteins besides TRKAκ-V5-His. 
These proteins were of higher molecular weight than the 
expected ~40 kD TRKAκ-V5-His protein and were not 
present in precipitates containing other TRKA isoforms. 
If this was a result of co-precipitation, it can be assumed 
that these protein interactions are so strong as to with-
hold the harsh detergent conditions of radioimmuno-
precipitation assay (RIPA) lysis buffer. Phosphorylated 
proteins of unknown origin were not seen with other 
overexpressed TRKA proteins.
Isoforms seemed to vary in the extent of autophospho-
rylation. To better characterize this variation, Western 
blot signals were quantified with densitometric analysis. 
Data was converted into an anti-pY to anti-V5 signal ratio 
(pY/V5) for each isoform and presented as a fold change 
relative to the pY/V5 ratio of TRKAII. Significance of dif-
ferences of these ratios over three independent experi-
ments was determined with Repeated Measures ANOVA 
and with a post hoc multiple comparisons test (Tukey–
Kramer). The results are shown in Fig. 5b.
When protein expression level is very high, such as in 
cancer, even those kinase receptors exhibit autocatalysis 
that under normal physiological conditions are repressed. 
In the current experiment, the amount of protein 
monomer was not the sole determinant of autophospho-
rylation, since for every isoform the strength of V5 signal 
does not correlate with the strength of pY signal. Most 
notably, TRKAγII-V5-His and TRKAδII-V5-His were 
sixteen times more phosphorylated relative to TRKAII-
V5-His. pY/V5 ratio difference between TRKAγII-V5-His 
and TRKAδII-V5-His was not statistically significant, 
as likely there are no biologically significant differences 
concerning autophosphorylation rate of these isoforms, 
since these proteins vary only by the presence or absence 
of a predicted signal peptide. TRKAεII-V5-His displayed 
two-fold smaller rate of simultaneous kinase activation 
as compared to TRKAγII and TRKAδII. This difference 
might have biological relevance, since TRKAεII pro-
tein almost entirely lacks cysteine-flanked leucine-rich 
motifs that could stimulate dimerisation in TRKAγII 
and TRKAδII. TRKAκ-V5-His, a protein corresponding 
to the intracellular domain of TRKAII had an autoacti-
vation capacity comparable to TRKAII, possibly because 
TRKAκ lacks extracellular domains which could facilitate 
dimerisation and subsequent autophosphorylation as 
seen for other putative TRKAII isoforms.
TRKAζII is a glycoprotein residing in intracellular 
compartments
We noticed that TRKAII-V5-His and TRKAζII-V5-His 
lysates showed signals from larger proteins than can be 
estimated (Fig.  5a). Based on an analogy to immunoblot 
pattern observed for TRKAII-V5-His it was assumed that 
TRKAζII-V5-His could also be glycosylated similarly to 
TRKAII. To clarify this issue, HEK293 cells were trans-
fected with expression constructs of TRKAII-V5-His, 
TRKAγII-V5-His and TRKAζII-V5-His, followed by treat-
ment with tunicamycin, an inhibitor of N-linked glyco-
sylation. Lysates were analyzed with an anti-V5 antibody. 
Tunicamycin inhibition was effective as tunicamycin-
treated cells transiently expressing TRKAII-V5-His con-
tained only the unmodified form of the receptor (Fig. 6a). 
TRKAγII-V5-His was included because it was the only 
novel putative TRKA isoform for which the Phobius pre-
diction tool estimated a membrane signal sequence and 
thus it could be directed to the ER-Golgi route where it 
can be glycosylated. However, since the predicted size of 
the protein without glycosylation coincided with the Mw 
of the protein seen on SDS-gel (Fig. 5a), it seemed that the 
signal sequence of TRKAγII is nonfunctional. In accord-
ance with this finding, tunicamycin did not change the 
electrophoretic mobility of TRKAγII and the intracellular 
localization of TRKAγII-V5-His appeared to be cytosolic 
(Fig. 6b). On the other hand, the disappearance of signal 
from the protein with bigger Mw in case of TRKAζII-
V5-His-transfected and tunicamycin-treated cells is a 
clear indication that this isoform is modified at least on 
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one of the five consensus N-glycosylation sites (N-X-S/T 
sequons) it has. This finding seems to place TRKAζII-V5-
His to the ER-Golgi route, where N-glycosyltransferases 
reside. However, as opposed to the full-length TRKAII, 
TRKAζII did not reach plasma membrane in HEK293 
cells transiently transfected with TRKAζII-V5-His expres-
sion plasmid (Fig. 6b).
Usually, proteins are targeted to the ER when nascent 
signal peptide is revealed during the first translational 
round [47]. Signal peptides are not conserved among 
secretory and integral proteins, but generally consist of 
20–30 residues with positively charged aa residues in the 
N-terminus followed by a hydrophobic core of at least 
six residues. However, yet undefined structural features 
seem to be also important [48]. Phobius prediction tool 
for signal peptides estimated that TRKAγII could be 
directed to plasma membrane while TRKAζII cannot. 
Although TRKAγII has a longer stretch of hydrophobic 
amino acids in the N-terminus compared to TRKAζII, 
this hydrophobic core is preceded by a lysine and gluta-
mate, whereas TRKAζII has two histidines in the N-ter-
minus (Fig. 6c). Only about 10 % of histidine residues are 
in a positively charged state at physiological pH, however, 
apparently this serves to be a recognizable signal peptide, 
whereas TRKAγII’s N-terminus does not.
TRKAκ localizes to the cytoplasm and the nucleus
Initial experiments with putative TRKA protein isoforms 
in HEK293 cells revealed that additionally to cytosolic dis-
tribution, TRKAκ-V5-His is also present in the nucleus. To 
confirm this finding, immunocytochemical analysis was 
carried out in HEK293 cells and primary rat cortical neu-
rons transfected with the expression construct encoding 
TRKAκ-V5-His or TRKAII-V5-His as a control. Although 
TRKAII-V5-His was restrained to the cytoplasm and the 
plasma membrane, the ability of TRKAκ-V5-His to local-
ize to the nucleus of neuronal cells was confirmed, how-
ever, various types of localization were observed (Fig. 7a). 
Therefore, this effect is not cell-type specific.
Since fixation and permeabilization procedures pre-
ceding immunocytochemistry can alter protein locali-
zation pattern, the nuclear translocation of TRKAκ was 
verified in HEK293 cells with live imaging of EGFP-
tagged protein by directly observing the fluorescence of 
EGFP. Moreover, TRKAκ-EGFP has a significantly bigger 
molecular weight (70 kDa) than TRKAκ-V5-His (42 kDa) 
a
b
Fig. 5 Autophosphorylation potential of a selection of TRKA protein isoforms. HEK293 cells were transfected with constructs encoding different 
putative TRKA isoforms. Untransfected cells were used as a negative control (neg). Isoforms were precipitated from lysates using rabbit antibody 
against V5-tag. a Equal amounts of immunoprecipitate were analyzed with SDS-PAGE and Western blot using mouse V5-antibody and mouse phos-
photyrosine antibody. b Immunoblot signals from three independent experiments were quantified and the phosphorylated fractions of proteins 
were defined as pY/V5 ratios, which were log transformed, mean centered and autoscaled for statistical analysis. Results from Tukey–Kramer multi-
ple comparisons test are compiled into a table. For graphic representation, data is expressed as a fold change relative to the pY/V5 ratio of TRKAII. 
Back-transformed mean values ± SEM bars are shown
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and cannot diffuse to the nucleus passively. The control 
EGFP displayed a uniform localization pattern, while in 
some cells the signal of TRKAκ-EGFP was clearly accu-
mulated in the cell nucleus (Fig. 7b).
To better describe this phenomenon, we used immu-
nocytochemistry to quantify the intracellular localiza-
tion of overexpressed TRKAκ-V5-His and TRKAκ-EGFP 
in HEK293 cells. While the control TRKAII-V5-His was 
restricted to cytosol and plasma membrane, as expected, 
TRKAκ with the same tag entered nucleus in more than 
80 % of cells and 3 % of cells expressing TRKAκ-V5-His 
displayed signal that was predominantly in the nucleus 
(Fig. 7c). On the other hand, EGFP protein was uniformly 
distributed between cytosol and nucleus in all cells exam-
ined. When TRKAκ was linked to EGFP, then the level of 
signal from cell nucleus exceeded that from the cytosol in 
25 % of cells (Fig. 7c). Therefore, our experiments clearly 
indicate that TRKAκ is able to enter cell nucleus.
There is no conventional nuclear localization signal 
(NLS) present in TRKA. Nevertheless, in the proximity of 
N-terminus of TRKAκ a signal sequence SPT that has been 
shown to mediate the recognition by Importin-7 (Imp7) 
was identified. There is numerous evidence of Imp7 trans-
locating a variety of proteins such as Smads, extracellular 
signal-regulated kinase 2 (Erk2) and early growth response 
protein 1 and glucocorticoid receptor (Egr-1) to the nucleus 
[49–52]. A hypothesis of the translocation of TRKAκ to the 
nucleus by Imp7 via the SPT sequence was proposed. Cel-
lular localization of TRKAκ-SPT-EGFP (lacking the puta-
tive signal sequence) bared no significant difference with 
TRKAκ-EGFP (data not shown). Therefore, it can be con-
cluded that the sequence eliminated was not responsible 
for the accumulation of the TRKA intracellular fragment to 
the nucleus and Imp7 was most probably not involved in 
the transportation of TRKAκ to the nucleus.
Discussion
TRKA gene organization and expression in human, mouse 
and rat
As more and more mRNA sequence information 
becomes available, it is becoming evident that overlap-
ping genes are more common than previously thought 




Fig. 6 TRKAζII-V5-His is a glycoprotein not targeted to the plasma 
membrane. HEK293 cells were transfected with plasmids encoding 
proteins TRKAII-V5-His, TRKAγII-V5-His and TRKAζII-V5-His. The proteins 
were detected using western blotting and an antibody against the 
V5-tag. a TRKAζII-V5-His is a glycoprotein. Cells were cultured with (+) 
or without (−) tunicamycin (Tm, 2 µg/ml), the inhibitor of N-linked 
glycosylation. Untransfected cells were used as a negative control 
(neg). b Intracellular localization pattern of tagged TRKA isoforms 
detected with immunocytochemical analysis. DNA was stained with 
DAPI, plasma membrane was visualized with Alexa Fluor 488-conju-
gated concanavalin A. Scale bar 5 µm. c The first 52 N-terminal amino 
acid residues of TRKAII, TRKAγII and TRKAζII. Amino acids that are 
considered to be more hydrophobic are in green, less hydrophobic 
are grey, amino acid residues with positive charges are underlined
(See figure on next page.) 
Fig. 7 TRKAκ isoform’s localization into the nucleus. a immunocytochemical analysis revealing TRKAκ-V5-His and TRKAII-V5-His localization in 
primary rat neurons and HEK293 cells. DNA was stained with DAPI. To mark glycoproteins embedded in the plasma membrane, Alexa Fluor 
488-conjugated concanavalin A (con A) was used, and TRKA-V5-His proteins were visualized with anti-V5-tag antibodies and secondary Alexa Fluor 
568-conjugated antibodies. Scale bar 5 µm. b Nuclear accumulation of EGFP-fused TRKAκ in HEK293 cells. Cells were transfected with constructs 
encoding TRKAκ-EGFP or EGFP, and mCherry-NLS (the marker for nucleus). Live cells were imaged with a confocal microscope. Scale bar 5 µm. c 
HEK293 were fixed and subjected to immunocytochemistry 24 h p.t. of expression constructs encoding TRKAII-V5-His, TRKAκ-V5-His, TRKAκ-EGFP or 
EGFP. The cells were visualized with confocal microscopy and counted by determining the localization of given protein of interest in n number of 
cells. The graph shows pooled results of two independent experiments. C = N, the signal was observed uniformly in cytosol and nucleus; C > N, the 
signal was greater in cytosol than in nucleus; C < N, the signal was greater in nucleus than in cytosol
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In this study we describe TRKA gene, which in human is 
overlapped by two genes of the opposite strand—INSRR 
and SH2D2A. More specifically, these genes are over-
lapped by novel TRKA 5′ exons A…D with the transcrip-
tion-initiation site in exon A. Despite our efforts, we 
were unable to identify these exons in mouse or rat. As 
the transcription-initiation sites of human TRKA exon A 
and SH2D2A are less than 1 kb apart, it can be speculated 
that the unidirectional promoter of SH2D2A has become 
bidirectional at one point in the evolutionary history of 
human, therefore giving rise to this novel 5′ terminus of 
TRKA. There is probably a complex interaction between 
the expression of these three genes, as they might influ-
ence each other in synergistic or competitive way during 
and after transcription. For example, the close proxim-
ity of INSRR and TRKA promoters might render the 
genomic region accessible to transcriptional machinery 
simultaneously for both genes. In accordance with this, 
it has been shown that TRKA and INSRR expression pat-
terns are highly similar [55]. On the other hand, TRKA 
exon D overlaps an exon of INSRR gene by more than 
80  bp and this might result in partly double-stranded 
mRNAs and gene silencing as the respective regions in 
mRNA transcripts are complementary.
It should be noted that while we did not identify novel 
5′ exons of rodent TrkA, no previous 5′ RACE analyses 
of rat TrkA were recorded in literature to our knowledge. 
We identified numerous additional transcription-initiation 
sites and alternative splicing patterns of human TRKA 
which indicate the possible existence of many protein iso-
forms. Overall—all of the tissues under study expressed 
many types of 5′ TRKA exons. The translatability of many 
of these proteins could be debated as most of these mRNAs 
contain uORFs. However, according to bioinformatics 
studies, approximately half of mammalian protein-coding 
transcripts contain uORFs [56]. It has been shown that 
even when a strong Kozak sequence surrounds the AUG in 
uORF or when up to four uORFs precede the main ORF, 
nearly 10 % of ribosomes are capable of leaky scanning or 
reinitiation up to five times [46]. The alternative transcripts 
carrying several uORFs could also use these sequences as 
a regulatory element for adjusting the specific protein lev-
els to match the necessities of the cell. Also, some of the 
uORFs may be inaccessible for ribosomes due to RNA 
secondary structure. It remains to be determined which of 
these novel transcripts represent functional TRKA mRNAs 
and which can be considered as transcriptional noise.
Characteristics of putative novel TRKA protein isoforms
In TRK proteins, a kinase monomer is kept in an inac-
tive conformation through autoinhibition mechanism 
(the projection of one tyrosine residue into the active 
site). However, since kinase domain structure allows the 
movement of its parts to some degree, every monomer 
is occasionally freed from inhibited state and is able to 
phosphorylate in trans [57]. This spontaneous activity is 
deterred by the properties of the extracellular domain, 
such as the presence of glycan side chains [21, 22]. In 
accordance to this, the autocatalysis rates of potential 
TRKA isoforms tested in this study were very different 
with the highest levels seen for TRKAγII, TRKAδII and 
TRKAεII. All these isoforms contain part of the extra-
cellular domain of the prototypic TRKAII and are not 
glycosylated, as indicated by protein mobility pattern on 
SDS-PAGE and the lack of functional membrane signal 
sequences which renders them inaccessible to N-glyco-
syltransferases that are located in the Golgi apparatus. 
Phosphorylation of TRKAγII and TRKAδII could also be 
enhanced by the presence of unique amino acid residue 
stretch encoded by exons A and D.
We identified a putative TRKA isoform TRKAζII which 
was glycosylated in the ER-Golgi route and must there-
fore possess a functional membrane-signal sequence. 
However, when overexpressed, this protein was not trans-
ported to the plasma membrane, but got stalled intracel-
lularly. Similarly, TRKAIII is also known to be retained 
intracellularly with a highly autoactivated TRKAIII-pool 
residing in the ER/Golgi intermediate compartment [27]. 
It has been suggested that TRKAIII is not directed to the 
plasma membrane, because it lacks a site for the addition 
of a glycan moiety acting as a signal for further translo-
cation. On the basis of current study, TRKAζII-V5-His 
seems to be confined to intracellular compartments simi-
larly to TRKAIII. TRKAζII protein contains the juxtam-
embrane region that is omitted in TRKAIII but just as 
TRKAIII it does not have the first Ig-like domain. Thus, 
the first Ig-like domain could serve an important regula-
tory function in the trafficking of TRKA protein.
Among several alternative TRKA variants, an interest-
ing putative isoform, termed TRKAκ, emerged from our 
study. The protein constitutes primarily of the receptor’s 
tyrosine kinase domain. There are several reasons why 
this variant drew our attention. First, it is noteworthy 
that while the alternative splicing pattern observed in rat 
and mouse bares little similarities to the complexity seen 
in humans, the expression of transcripts with exons 9a 
and 10a that contribute to TRKAκ-encoding mRNAs was 
detected in all species examined. Second, these mRNAs 
have a distinct expression pattern in different tissues, 
leaving room for further speculation about the possible 
importance of this isoform in diverse cellular frame-
works. The rationale for further investigations of this 
protein includes also the possibility that proteolysis may 
generate a TRKAκ-like fragment, as under excitotoxic 
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conditions or in response to amyloid-β peptide the highly 
similar TRKB receptor has been recently shown to be 
subjected to proteolytic cleavage, resulting in a kinase-
domain containing soluble protein fragment [58–60]. 
This type of process has also been detected for another 
receptor tyrosine kinase called erythroblastic leukemia 
viral oncogene homolog-4 (ErbB-4). The ectodomain of 
ErbB-4 is cut by metalloprotease and the intracellular 
domain that is cleaved by γ-secretase is thereafter trans-
located to nucleus [61]. Cleavage of the TRKA extracel-
lular domain producing an ectodomain fragment and 
membrane-bound truncated TRKA fragments with 
intracellular kinase domain has been demonstrated, but 
no soluble fraction of TRKA kinase domain has yet been 
discovered [62].
The most intriguing property of TRKAκ is undoubt-
edly its intracellular localization which varies from cyto-
solic to nuclear. Under physiological conditions passive 
flux through nuclear pore complex is very restricted 
for molecules bigger than 30 kDa [63]. Thus, a TRKAκ-
like protein (35  kDa) especially when it’s EGFP-tagged 
(Σ  ≈  70  kDa) would only gain access to the nucleus 
with the aid of active transport or facilitated diffusion. 
Appearance of distribution patterns where TRKAκ-V5-
His or TRKAκ-EGFP signal was more strongly detected 
in the cytosol or the nucleus could suggest that the move-
ment of TRKAκ to the nucleus is regulated, since active 
transport of TRKAκ might be dependent on the availabil-
ity of adapter proteins that are only expressed in a cer-
tain time frame during cell-cycle or under certain cellular 
physiological states. Alternatively, TRKAκ could shift 
towards passive nuclear accumulation when high-affinity 
nuclear anchoring proteins in the nucleus do not allow its 
export and/or impede its free diffusion.
Previously, by using the method of immunocytochem-
istry, TRKA has been detected in the nuclei of various 
cells, such as melanocytic tumors [64], ovarian carcinoma 
[65], human glioma cell line U251 [66], rat pheochromo-
cytoma cell line PC12 and cultured hepatic stellate cells 
[67]. In liver cells TRKA nuclear immunoreactivity was 
observed when antibody against C-terminus was used, 
whereas antibody against N-terminus did not reveal 
TRKA. Overall, it is not clear whether nuclear TRKA 
seen in those studies represents the whole receptor, its 
proteolytic fragment, an alternative isoform or non-
specific staining. Our current study implies that neither 
HEK293 cells nor rat primary neurons contain transport-
ing machinery necessary for whole receptor translocation 
into the nucleus, although this could possibly be other-
wise in different cell types. However, our results estab-
lished that TRKAκ tagged to V5-His or EGFP is definitely 
present in the nucleus whether it is encoded by specific 
mRNAs or proteolytically generated from the full-length 
receptor.
As compared to many other TRKA isoforms, TRKAκ 
displayed relatively low autocatalysis rate which is par-
ticularly interesting in the light of the finding that TRKAκ 
was bound to other pY-proteins, while for more highly 
phosphorylated isoforms of TRKA it was not possible to 
detect interactions of this intensity. Presumably only the 
small p-TRKAκ fraction was capable of interacting with 
these proteins, since they were tyrosine-phosphorylated 
and it can be assumed that this modification was medi-
ated by the kinase activity of p-TRKAκ. Alternatively, 
the situation may be reversed as some of these proteins 
may be tyrosine kinases phosphorylating TRKAκ. How-
ever, given that this was the only TRKA isoform display-
ing nuclear localization, it can be suggested that there are 
high-affinity substrates for TRKA that may reside inside 
the nucleus.
Identical protein to TRKAκ was characterized by Cou-
lier and coworkers when different deletion-mutants of 
TRKA were assessed on the ability to transform NIH 
3T3 cells [68]. They found that this protein is a func-
tional kinase, but has no transforming ability just as 
the full-length receptor. Interestingly, in melanomas, 
nuclear expression of phosphorylated TRKA was more 
pronounced in primary tumors relative to metastases 
[64]; however, in ovarian carcinoma nuclear expression 
was not more characteristic to any stage of cancer pro-
gression [65]. Thus, it is unclear whether TRKA nuclear 
activity contributes to malignant phenotype or aids to 
maintain a stable state.
The novel cytoplasmic and nuclear isoforms of TRKA 
cannot be activated by NGF or NT-3 because neurotro-
phins are directed to membrane-bound ER-lumen and 
to the vesicles of the Golgi complex already during their 
synthesis. Therefore, their interaction with those TRKA 
isoforms is sterically impossible. However, these TRKA 
proteins can undergo spontaneous autoactivation or, 
alternatively, there might be some other activating factors 
within the cell which are yet unidentified.
Conclusions
TRK receptors have crucial roles in processes with vari-
ous outcomes such as proliferation, survival and differ-
entiation. Thus, the activity of these receptors has to be 
regulated for the correct cellular fate. Control at mRNA 
level through alternative splicing and several alterna-
tive transcription initiation sites provides mechanisms 
to diversify the pool of TRK proteins with different 
properties.
In this study, TRKA transcripts were studied in sil-
ico, by 5′ RACE and by semiquantitative analyses. The 
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expression patterns of alternative TRKA transcripts were 
analyzed in different human brain regions and periph-
eral human, mouse and rat tissues. Many novel alterna-
tive transcript variants were detected in human tissues 
and the presence of a large number of TRKA protein iso-
forms was predicted that differ in N-termini and protein 
sequences of the extracellular domain encoded by alter-
natively spliced exons. In rat and mouse tissues the splic-
ing observed was less intricate. Our experiments showed 
that soluble TRKA isoforms, which contain parts of ung-
lycosylated extracellular domain, are highly autocatalytic 
in comparison to plasma membrane-embedded glyco-
sylated TRKAII receptor. One of the putative isoforms, 
TRKAζII, is a glycoprotein residing in intracellular com-
partments similarly to isoform TRKAIII. Therefore, it can 
be inferred that the first Ig-like domain in TRKAI/II that 
is missing in both TRKAIII and TRKAζII, is necessary for 
the translocation of receptor to the plasma membrane. 
One of the putative isoforms that is composed mainly 
of the kinase domain, named TRKAκ, displayed a rela-
tively low level of autocatalysis rate. Interestingly, TRKAκ 
was detected in the nucleus and cytoplasm of transiently 
transfected fixed as well as live cells.
These findings lay ground to future studies in the field 
of alternative TRKA isoforms, as there seems to be an 
immensely larger variability among TRKA proteins with 
different properties than is presently known.
Methods
All experiments with human postmortem tissues were 
approved by the ethics committee of medical studies at 
National Institute for Health Development of Estonia 
(Permit Number: 402). The protocols involving animals 
were approved by the ethics committee of animal experi-
ments at Ministry of Agriculture of Estonia (Permit Num-
ber: 45). Human RNAs used in this study were acquired 
from BD Biosciences (thymus, muscle, heart, prostate, 
testis, pancreas, kidney and colon samples), from Bio-
Chain Inc. (human spleen and fetal tissues), or were 
extracted from frozen adult  human  postmortem brain 
regions obtained from North Estonian Regional Hospital, 
Tallinn. Rat tissues were obtained from Sprague–Dawley 
rats and mouse tissues from NMRI mice housed under a 
12 h light/dark cycle in local animal facility with ad libi-
tum access to water and food.
RT‑PCR and 5′ RACE
In silico analysis of the TRKA gene structure and tran-
scripts, reverse transcription and PCR methodology 
have been described before [69]. 5′ RACE experiments 
were conveyed with GeneRacer Kit (Invitrogen) accord-
ing to the manufacturer’s protocol (Invitrogen). For PCR, 
HotFire polymerase from Solis Biodyne was used. All 
primers used in this study are listed in Additional file 2, 
TRKA ESTs identified with sequencing have been sub-
mitted and the corresponding GenBank accession num-
bers can be found in Additional file 3.
Generation of expression constructs
To generate the V5-His-tagged TRKAII isoform, PCR 
was conducted to amplify the coding region from human 
frontal cerebral cortex cDNA and cloned into pcDNA3.1 
(Invitrogen). Sequences encoding N-terminal parts of 
different TRKA isoforms were amplified from human 
frontal lobe or muscle cDNA and ligated with plasmid 
pTZ57R/T of InsTAclone™ PCR Cloning Kit (Fermentas). 
Verified sequences were subcloned into the pcDNA3.1/
TRKAII-V5-His vector using the following restriction 
enzymes: HindIII and NarI (for pcDNA3.1/TRKAγII-V5-
His), XbaI and Eco47III (for pcDNA3.1/TRKAδII-V5-
His), HindIII and BalI (for pcDNA3.1/TRKAεII-V5-His), 
HindIII and PagI (for pcDNA3.1/TRKAζII-V5-His), XbaI 
and NcoI (for pcDNA3.1/TRKAκ-V5-His).
EGFP-tagged TRKAκ was generated by excising 
the V5-His tag-coding sequence from the pcDNA3.1/
TRKAκ-V5-His plasmid and substituting it with EGFP-
coding sequence from pEGFP-N2 (Clontech). For this, 
Cfr42I (in case of pcDNA3.1/TRKAκ-V5-His) and NotI 
(for pEGFP-N2) restriction enzymes were used, fol-
lowed by DNA-blunting with T4 DNA polymerase in the 
presence of dNTPs and a final restriction with BamHI 
enzyme. Restriction products of interest were ligated. All 
restriction enzymes were purchased from Fermentas and 
all DNA constructs were verified by sequencing.
Cell culture and transfection
HEK293 cells were grown in Minimum Essential Medium 
(MEM) with Earle’s salts and l-Glutamine containing 
10 % fetal bovine serum (FBS) and 1 % penicillin/strep-
tomycin. LipoD293™ DNA In Vitro Transfection Reagent 
(SignaGen) was used in HEK293 cell transfections. PC12 
cells were maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM) containing 6 % FBS, 6 % horse serum 
(HS) and 1  % penicillin/streptomycin. SH-SY5Y cells 
were grown in DMEM/Ham’s F12 in 1:1 ratio, contain-
ing 10 % FBS and 1 % penicillin/streptomycin. For NGF 
treatments, growth medium with 50 ng/ml of NGF (Pep-
roTech) was added 5 min prior to harvesting the cell cul-
ture. All growth media components were purchased from 
PAA Laboratories GmbH.
Cerebral cortex was dissected from Sprague–Dawley 
rat embryos at embryonic day 21. Cells were dissoci-
ated with 0.25 % trypsin (Invitrogen), followed by treat-
ment with 0.05  % DNase I (Roche). Cells were grown 
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on poly-l-lysine-coated cover slips in Neurobasal A 
medium (Invitrogen) with B27 supplement (Invitrogen), 
1  % penicillin/streptomycin, and 1  mM  l-glutamine 
(PAA Laboratories GmbH). Mitotic inhibitor 5-fluoro-2′-
deoxyuridine (Sigma) was added to the medium (10 μm) 
at 2  days in  vitro (DIV). Primary neurons were trans-
fected at 7 DIV using Lipofectamine 2000 transfection 
reagent (Invitrogen) as advised by the manufacturer.
The Silencer Select small interfering RNA (siRNA), 
with nucleotide sequence GUACUUCAGUGAUAC-
CUGUtt, targeting rat TrkA and negative unspecific 
siRNA (#1) were from Ambion (Life Technologies). SiR-
NAs were transfected to PC12 cells with Lipofectamine 
RNAiMax Transfection Reagent (Invitrogen) with final 
10 nM siRNA concentration, according to the manufac-
turer’s instructions. Cells were harvested 24–48  h after 
transfection.
Western blotting
Western blotting has been described previously [70]. 
Antibodies used included: rabbit anti-TRKA (#06-574; 
1:1000) and mouse anti-pY (#05-1050; 1:2000) from 
Millipore; rabbit anti-TRK (#4609; 1:500) and rabbit 
anti-phospho-TRKA (#9141; 1:1000) from Cell Sign-
aling; mouse anti-V5 (#R960-25; 1:5000) from Invit-
rogen; mouse anti-GAPDH (#G8795; 1:5000) from 
Sigma-Aldrich.
N-linked glycosylation was inhibited from 6  h after 
transfection by adding tunicamycin (2  µg/ml; Appli-
Chem) and cells were lysed 9 h later in RIPA buffer.
Immunoprecipitation, immunofluorescence and confo-
cal microscopy were done as described previously [70].
Live imaging
All live imaging experiments were done at 37  °C, in a 
chamber supplied with 5  % CO2. Zeiss LSM 5 DUO 
confocal laser scanning microscope with Zeiss confocal 
scan software was used for imaging. Coverslips contain-
ing cultured HEK293 cells were transferred into a metal 
chamber. For all experiments a 63× glycine immersion 
fluorescence objective (LSI Plan-Neofluar 63×/1,3 Imm 
Korr DIC M27) was used.
Additional files
Additional file 1: Sequences of putative TRKA protein isoforms. Red 
indicates sequences that are not found in TRKAII isoform. (A) Isoforms 
with different N-termini compared to TRKAII. (B) Exclusion of parts of 
the extracellular domain as exemplified in the case of isoforms with the 
conventional N-terminus.
Additional file 2: Primers and cycling conditions used in this study.
Additional file 3: GenBank accession numbers of ESTs identified in this 
study.
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